The development of targeted therapies has led to personalized medicine for advanced non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma (ADC) with actionable genetic alterations, such as EGFR, ALK, KRAS, and ROS1. The gene discussed is KRAS; the disease is lung adenocarcinoma.